- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02077179
Health Improvement After Pregnancy (HIP) Program Randomized Control Trial (HIP)
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Ontario
-
Kingston, Ontario, Canadá, K7L 2V7
- Queen's Unviersity
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- must own or have daily access to one or more of the following; smart phone, tablet or laptop computer
Exclusion Criteria:
- Living greater than 100km from Kingston General Hospital
- Having an existing and long term contraindication to exercise at the time of recruitment
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: Standard of Care
Participants in this arm will receive care as per the usual standards from Kingston General Hospital and their primary care provider.
|
|
|
Experimental: HIP Program
Participants in this arm will follow the HIP Program in addition to their usual care from Kingston General Hospital and their primary care provider.
|
The entirety of the HIP Program is delivered through an interactive mobile website. The physical activity portion of the program consists of daily step counting, prescribed aerobic activity, structured strength and toning workouts, and daily stretching. The program was designed by a local trainer, specializing in postnatal exercise, to increase gradually in intensity, while encouraging a more active lifestyle. The program is designed to be completed at home with minimal equipment. The nutrition portion of the program consists of 16 video tutorials developed by a local Registered Dietitian and weekly diet logs. The video tutorials cover all aspects of healthy eating, from the basics of Canada's Food Guide, to smart snacking, to eating healthy over the holidays. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Metabolic Syndrome Z Score
Prazo: 32 weeks postpartum
|
The primary outcome measure is the metabolic syndrome (MetS) z score, a continuous score of the five metabolic syndrome variables that make up the Adult Treatment Panel (ATP) III diagnostic criteria (waist circumference, blood pressure, high density lipoprotein, triglycerides and glucose).
Differences between study arms will be compared.
|
32 weeks postpartum
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adherence to the HIP Program; Percent of Workouts Completed
Prazo: 32 weeks postpartum
|
Adherence to the HIP Program will be assessed based on the number of times a participant indicates using the mobile website that a prescribed workout has been completed.
This outcome will only be measured in the intervention arm.
|
32 weeks postpartum
|
|
Differences in Biochemical Cardiovascular Risk Markers
Prazo: 32 weeks postpartum
|
Differences between study arms for the following biochemical cardiovascular risk markers will be assessed at 32 weeks postpartum; lipid profile, fasting glucose, glycated hemoglobin, high sensitivity C-reactive protein, and urine microalbumin creatinine ratio.
|
32 weeks postpartum
|
|
Change in Anthropomorphic Measurements and Blood Pressure from Baseline at Midpoint
Prazo: 20 weeks postpartum
|
Changes in systolic blood pressure, diastolic blood pressure and weight from baseline measures at 6-8 weeks postpartum will be assessed at the midpoint of the program at 20 weeks postpartum.
Differences between study arms will be compared.
|
20 weeks postpartum
|
|
Change in Anthropomorphic Measurements and Blood Pressure from Baseline at Study Completion
Prazo: 32 weeks postpartum
|
Changes in systolic blood pressure, diastolic blood pressure and weight from baseline measures at 6-8 weeks postpartum will be assessed at the midpoint of the program at 32 weeks postpartum.
Differences between study arms will be compared.
|
32 weeks postpartum
|
|
Change in Anthropomorphic Measurements and Blood Pressure from Midpoint to Study Completion
Prazo: 32 weeks postpartum
|
Changes in systolic blood pressure, diastolic blood pressure, weight, body mass index, hip circumference, and waist circumference from midpoint measures at 20 weeks postpartum will be assessed at the end of the program at 32 weeks postpartum.
Differences between study arms will be compared.
|
32 weeks postpartum
|
|
Adherence to the HIP Program; Percent of Step Counting Completed
Prazo: 32 weeks postpartum
|
Adherence to the HIP Program will be assessed based on the number of times a participant uses the mobile website to log their daily step count total.
The number of times that the logged step count meets or exceeds the prescribed number of daily steps will also be assessed.
This outcome will only be measured in the intervention arm.
|
32 weeks postpartum
|
|
Adherence to the HIP Program; Percent of Dietary Logs Completed
Prazo: 32 weeks postpartum
|
Adherence to the HIP Program will be assessed based on the number of times a participant uses the mobile website to enter the weekly dietary log.
The number of times that the dietary log meets the prescribed intake for each of the Canada's Food Guide food groups will also be assessed.
This outcome will only be measured in the intervention arm.
|
32 weeks postpartum
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Graeme N Smith, MD,PhD,FRCSC, Queen's University
Publicações e links úteis
Publicações Gerais
- Smith GN, Pudwell J, Roddy M. The Maternal Health Clinic: a new window of opportunity for early heart disease risk screening and intervention for women with pregnancy complications. J Obstet Gynaecol Can. 2013 Sep;35(9):831-839. doi: 10.1016/S1701-2163(15)30841-0. No abstract available.
- Cusimano MC, Pudwell J, Roddy M, Cho CK, Smith GN. The maternal health clinic: an initiative for cardiovascular risk identification in women with pregnancy-related complications. Am J Obstet Gynecol. 2014 May;210(5):438.e1-9. doi: 10.1016/j.ajog.2013.12.001. Epub 2013 Dec 4.
- Smith GN, Pudwell J, Walker M, Wen SW. Risk estimation of metabolic syndrome at one and three years after a pregnancy complicated by preeclampsia. J Obstet Gynaecol Can. 2012 Sep;34(9):836-841. doi: 10.1016/S1701-2163(16)35382-8.
- Smith GN, Pudwell J, Walker M, Wen SW. Ten-year, thirty-year, and lifetime cardiovascular disease risk estimates following a pregnancy complicated by preeclampsia. J Obstet Gynaecol Can. 2012 Sep;34(9):830-835. doi: 10.1016/S1701-2163(16)35381-6.
- Smith GN, Walker MC, Liu A, Wen SW, Swansburg M, Ramshaw H, White RR, Roddy M, Hladunewich M; Pre-Eclampsia New Emerging Team (PE-NET). A history of preeclampsia identifies women who have underlying cardiovascular risk factors. Am J Obstet Gynecol. 2009 Jan;200(1):58.e1-8. doi: 10.1016/j.ajog.2008.06.035. Epub 2008 Aug 8.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- OBGY-249-14
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .